In the current study we assessed the effects of Notch1, EGFR and PDGFR inhibitors as a means of investigating GBM CSC responses to disruption of specific intracellular signaling relevant to GBM CSC maintenance. The gene discussed is PDGFRB; the disease is glioblastoma.